Ashleigh Furlong is a health care reporter at Bloomberg. She specializes in public health, pharmaceutical regulation, and consumer health, covering a wide range of topics including drugs and medication, immunology, and oncology. Ashleigh's work has been featured in prominent outlets such as Yahoo Finance, Scientific American, and TIME.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ashleigh Furlong's coverage spans a variety of topics, with a significant focus on healthcare and pharmaceutical issues. She places particular emphasis on government announcements, legal policy regulation, and breaking news.
Given her extensive coverage of healthcare and pharmaceutical matters, she may be interested in receiving pitches related to these areas. For instance, providing insights into recent health crises or developments in drug policies could resonate well with her area of expertise.
It is important to note that Ashleigh also covers international relations and conflicts such as the Middle East conflict and Russia-Ukraine conflict. Therefore, if your pitch relates to any evolving stories within these areas or includes relevant data citations from reputable sources, it might catch her attention.
Additionally, considering Ashleigh's frequent reference to government announcements and legal policy regulations in her coverage attributes suggests that she would likely appreciate pitches offering analysis or expert commentary on new legislative measures impacting the sectors she covers.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ashleigh Furlong, Jason Gale
Frontline health workers in eastern Democratic Republic of Congo may soon be offered an experimental vaccine against the Bundibugyo strain of Ebola, as researchers test whether it can provide partial protection while a strain-specific vaccine remains months away.
By: Ashleigh Furlong, Lucca De Paoli
U-Test’s brand ambassadors aren’t medical professionals. The British company sells test kits for sexually transmitted infections, and bowel and prostate health over social media, so the faces of its business
AstraZeneca Plc reported higher-than-expected profit, buoyed by blockbuster cancer medicines, as focus turns to the company’s next generation of oncology drugs.
GSK Plc plans annual savings of £1.9 billion ($2.5 billion) by 2029, as the drugmaker invests more in its pipeline to replace revenue from the looming patent expiry of an HIV medicine.
Sanofi reported better-than-expected profit growth and nudged its guidance higher, helped by surging demand for its top-selling skin and asthma medicine Dupixent.
GSK Plc agreed another deal with British biotech Relation Therapeutics Ltd. to use artificial intelligence to speed up drug development.
By: Ashleigh Furlong, Dinesh Nair, Kelly Gilblom, Michelle F. Davis
AstraZeneca Plc has explored an acquisition of Bristol Myers Squibb Co., in a megadeal that would create one of the world's largest drugmakers, according to people familiar with the matter.
(Bloomberg) -- KKR has agreed to buy US medical device company Integer Holdings Corp. in an all-cash deal valued at about $5.7 billion.
By: Ashleigh Furlong, Sonja Wind
AstraZeneca has explored a potential tie-up with US peer Bristol-Myers Squibb.
Smith & Nephew Plc cut its revenue-growth forecast for the year after weaker demand for hip and knee implants in the US.
